AVTX logo

AVTX
Avalo Therapeutics Inc

13,664
Mkt Cap
$404.72M
Volume
1.11M
52W High
$20.72
52W Low
$3.39
PE Ratio
-2.91
AVTX Fundamentals
Price
$17.76
Prev Close
$16.70
Open
$16.39
50D MA
$15.54
Beta
1.70
Avg. Volume
809,789.18
EPS (Annual)
-$5.84
P/B
3.96
Rev/Employee
$1,787.88
$147.49
Loading...
Loading...
News
all
press releases
Avalo Therapeutics (NASDAQ:AVTX) Insider Mittie Doyle Sells 679 Shares
Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) insider Mittie Doyle sold 679 shares of the firm's stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price...
MarketBeat·14h ago
News Placeholder
More News
News Placeholder
Avalo Therapeutics (NASDAQ:AVTX) CFO Sells $133,807.83 in Stock
Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) CFO Christopher Ryan Sullivan sold 7,979 shares of the business's stock in a transaction on Wednesday, April 1st. The stock was sold at an...
MarketBeat·14h ago
News Placeholder
Avalo Therapeutics (NASDAQ:AVTX) CFO Christopher Ryan Sullivan Sells 7,980 Shares
Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) CFO Christopher Ryan Sullivan sold 7,980 shares of the firm's stock in a transaction dated Thursday, April 2nd. The stock was sold at an...
MarketBeat·14h ago
News Placeholder
Wall Street Analysts Predict an 113.34% Upside in Avalo Therapeutics (AVTX): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 113.3% in Avalo Therapeutics (AVTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·20h ago
News Placeholder
5 Small Drug Stocks to Buy as Sector Recovery Gains Strength
Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, CPRX, TBPH, RLMD and AVTX may prove to be good additions to one's portfolio.
Zacks·2d ago
News Placeholder
Avalo Therapeutics (NASDAQ:AVTX) Upgraded to "Hold" at Wall Street Zen
Wall Street Zen upgraded Avalo Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Sunday...
MarketBeat·6d ago
News Placeholder
HC Wainwright Issues Positive Outlook for AVTX Earnings
Avalo Therapeutics, Inc. (NASDAQ:AVTX - Free Report) - Investment analysts at HC Wainwright lifted their Q1 2026 earnings per share (EPS) estimates for Avalo Therapeutics in a research report issued...
MarketBeat·8d ago
News Placeholder
CORT Rises on FDA Nod to Lifyorli in Platinum-Resistant Ovarian Cancer
Corcept jumps after FDA approves Lifyorli combo for platinum-resistant ovarian cancer, marking the first-of-its-kind treatment.
Zacks·9d ago
News Placeholder
Avalo Therapeutics (NASDAQ:AVTX) Stock Price Expected to Rise, HC Wainwright Analyst Says
HC Wainwright lifted their price objective on shares of Avalo Therapeutics from $25.00 to $40.00 and gave the company a "buy" rating in a research note on Wednesday...
MarketBeat·10d ago
News Placeholder
Avalo Therapeutics (NASDAQ:AVTX) Earns Buy Rating from BTIG Research
BTIG Research reiterated a "buy" rating and set a $40.00 price objective on shares of Avalo Therapeutics in a report on Tuesday...
MarketBeat·11d ago
<
1
2
...
>

Latest AVTX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.